Product Description
MM-302 (Gancotamab) is a liposome containing doxorubicin and conjugated to a monoclonal antibody against the ERBB2 (HER2) receptor, which improves efficacy while reducing toxicityÊ (Sourced from: https://ckb.jax.org/drug/show/7251)
Mechanisms of Action: ERBB2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merrimack
Company Location: CAMBRIDGE MA 02142
Company CEO: Gary L. Crocker
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Breast Cancer
Phase 1: Brain Cancer|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02735798 | P1 |
Withdrawn |
Brain Cancer |
2017-06-01 |
|
2014-003159-73 | P2 |
Terminated |
Breast Cancer |
2016-12-31 |
|
HERMIONE | P3 |
Terminated |
Breast Cancer |
2016-12-01 |
|
MM-302-02-01-01 | P1 |
Unknown status |
Breast Cancer |
2016-08-01 |